Lyra Therapeutics Inc (LYRA)
$0.01
$-0.19
(-95.00%)
As on 31-Aug-2026 14:13EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-65.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.7
-
Debt to Equity
-2.8
-
Book Value
$--
-
EPS
$-1.9
-
Face value
--
-
Shares outstanding
1,774,882
6 Years Aggregate
CFO
$-174.05 Mln
EBITDA
$-207.32 Mln
Net Profit
$-204.54 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
| -99.7 | -97.9 | -98.6 | -99.9 | -96.1 | -87.7 | -- |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
| -70.2 | -96.0 | 66.9 | -28.0 | -61.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
|
0.0 | 0.4 | 0.4 | -28.9 | -7,106.3 | -6595 | -- | 7.1 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 147.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Lyra Therapeutics Inc (LYRA)
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver... medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Read more
-
Executive Chairman
Dr. Harlan W. Waksal M.D.
-
Executive Chairman
Dr. Harlan W. Waksal M.D.
-
Headquarters
Watertown, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Lyra Therapeutics Inc (LYRA)
What is the current share price of Lyra Therapeutics Inc (LYRA) Today?
The share price of Lyra Therapeutics Inc (LYRA) is $0.01 (NASDAQ) as of 31-Aug-2026 14:13 EDT. Lyra Therapeutics Inc (LYRA) has given a return of -96.1% in the last 3 years.
What is the current PB & PE ratio of Lyra Therapeutics Inc (LYRA)?
Since, TTM earnings of Lyra Therapeutics Inc (LYRA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.65 |
-4.46 |
2024 |
-0.14 |
1.16 |
2023 |
-5.14 |
3.61 |
2022 |
-1.81 |
1.24 |
2021 |
-1.34 |
1.65 |
What is the 52 Week High and Low of Lyra Therapeutics Inc (LYRA)?
The 52-week high and low of Lyra Therapeutics Inc (LYRA) are Rs 8.75 and Rs 0.00 as of 01-Sep-2026.
What is the market cap of Lyra Therapeutics Inc (LYRA)?
Lyra Therapeutics Inc (LYRA) has a market capitalisation of $ 0 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Lyra Therapeutics Inc (LYRA)?
Before investing in Lyra Therapeutics Inc (LYRA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.